Published June 21, 2021
- Clinical evidence suggests that the JAK inhibitor Inrebic should be reimbursed as a treatment option for adults with myelofibrosis who cannot take or tolerate Jakavi. Inrebic cannot be prescribed to those who progress on Jakavi.
- There is insufficient evidence to justify a cost premium for Inrebic over other JAK inhibitors reimbursed for the treatment of myelofibrosis.
- If Inrebic is not reimbursed by public payers, best available therapy will be the only other treatment option for patients who cannot take Jakavi.